Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
$5.16
$5.42
$3.56
$12.92
$291.20M0.68365,652 shs951,406 shs
Cryoport, Inc. stock logo
CYRX
Cryoport
$5.46
-2.2%
$5.81
$4.58
$17.41
$272.51M1.81545,628 shs268,163 shs
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
$22.93
+0.6%
$22.54
$2.50
$22.94
$71.77M0.1419,700 shs50,800 shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$3.36
-21.7%
$5.02
$3.08
$19.71
$234.02M0.351.05 million shs5.52 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
+0.78%-0.58%-3.37%-31.11%-43.79%
Cryoport, Inc. stock logo
CYRX
Cryoport
-0.71%-0.18%-8.22%-27.81%-65.53%
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
0.00%0.00%0.00%0.00%+2.83%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-1.61%+6.72%-31.58%-32.33%-52.49%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
2.5415 of 5 stars
4.71.00.00.02.21.70.0
Cryoport, Inc. stock logo
CYRX
Cryoport
2.3795 of 5 stars
3.41.00.00.02.53.30.6
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
4.0415 of 5 stars
4.53.00.00.03.44.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3.38
Buy$30.00481.40% Upside
Cryoport, Inc. stock logo
CYRX
Cryoport
2.83
Moderate Buy$11.67113.68% Upside
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
0.00
N/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3.00
Buy$21.83549.80% Upside

Current Analyst Ratings Breakdown

Latest LABP, PHAT, ATXS, and CYRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$47.00
4/21/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
4/17/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$12.00 ➝ $10.00
4/16/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/16/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/10/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
4/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
4/1/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/A$3.33 per shareN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
$228.39M1.19$0.32 per share16.95$9.45 per share0.58
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
$18M3.99N/AN/A$7.41 per share3.09
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$55.25M4.24N/AN/A($1.27) per share-2.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$72.89M-$1.67N/AN/AN/AN/A-43.58%-29.36%5/8/2025 (Estimated)
Cryoport, Inc. stock logo
CYRX
Cryoport
-$99.59M-$2.49N/AN/AN/A-70.08%-13.35%-6.43%5/7/2025 (Estimated)
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
-$21.93M-$3.99N/AN/AN/AN/A-73.00%-63.00%N/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$201.59M-$5.35N/AN/AN/A-1,292.14%N/A-79.57%5/1/2025 (Estimated)

Latest LABP, PHAT, ATXS, and CYRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.48N/AN/AN/AN/AN/A
5/7/2025Q1 2025
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.28N/AN/AN/A$56.19 millionN/A
5/1/2025Q1 2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$1.06-$1.15-$0.09-$1.31$27.91 million$28.52 million
3/11/2025Q4 2024
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.45-$0.44+$0.01-$0.44N/AN/A
3/4/2025Q4 2024
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.33-$0.42-$0.09-$0.42$58.71 million$59.53 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
N/AN/AN/AN/AN/A
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
N/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/A
22.38
22.38
Cryoport, Inc. stock logo
CYRX
Cryoport
0.48
5.70
5.32
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
N/A
4.43
4.43
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
5.73
5.68

Institutional Ownership

CompanyInstitutional Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
98.98%
Cryoport, Inc. stock logo
CYRX
Cryoport
92.90%
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
49.06%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
99.01%

Insider Ownership

CompanyInsider Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
2.90%
Cryoport, Inc. stock logo
CYRX
Cryoport
10.10%
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
1.30%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
24.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3056.43 million54.80 millionOptionable
Cryoport, Inc. stock logo
CYRX
Cryoport
1,02049.91 million44.44 millionOptionable
Landos Biopharma, Inc. stock logo
LABP
Landos Biopharma
193.13 million3.09 millionNot Optionable
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
11069.65 million51.90 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astria Therapeutics stock logo

Astria Therapeutics NASDAQ:ATXS

$5.16 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$5.16 0.00 (-0.10%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Cryoport stock logo

Cryoport NASDAQ:CYRX

$5.46 -0.12 (-2.15%)
Closing price 04:00 PM Eastern
Extended Trading
$5.36 -0.11 (-1.92%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Landos Biopharma stock logo

Landos Biopharma NASDAQ:LABP

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Phathom Pharmaceuticals stock logo

Phathom Pharmaceuticals NASDAQ:PHAT

$3.36 -0.93 (-21.68%)
Closing price 04:00 PM Eastern
Extended Trading
$3.38 +0.02 (+0.57%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.